Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin (Bharat Serums and Vaccines)
- Development stage
- Unknown
- Lead developer
- Zydus Lifesciences
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Nudoxa is a non-pegylated liposomal formulation of doxorubicin hydrochloride, an anthracycline chemotherapy agent. Developed by Bharat Serums and Vaccines (part of the Bharat Daftary Group) in collaboration with Zydus, it is designed to optimize the therapeutic index of doxorubicin by altering its pharmacokinetic profile. The drug works by intercalating into DNA and inhibiting the enzyme DNA topoisomerase II, which leads to DNA strand breaks and prevents cancer cell replication. The liposomal delivery system, utilizing distearoyl-phosphatidylcholine, allows for prolonged circulation in the bloodstream and preferential accumulation in tumor tissues via the enhanced permeability and retention (EPR) effect. Unlike pegylated liposomal doxorubicin, this non-pegylated version is specifically designed to avoid the high incidence of palmar-plantar erythrodysesthesia (hand-foot syndrome), a common dose-limiting side effect of pegylated formulations. It is indicated for the treatment of various malignancies, including breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma.
- Brand names
- Nudoxa
- Other names
- non-pegylated liposomal doxorubicinNPLDdoxorubicin hydrochloride non-pegylated liposomal
02
Targets
DNATOP1 (DNA Topoisomerase I)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on doxorubicin (Bharat Serums and Vaccines).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin (Bharat Serums and Vaccines).